Screener
Xencor XNCR Q2 2026 earnings
Reported August 5, 2026 · After market close
Revenue$51.2MBeat by $32.3M
EPS-$0.29Beat by $0.51
Revenue estimate$18.9M
EPS estimate-$0.80
“Enrollment remains on track for updates later this year for XmAb942 in the XENITH-UC study and for our two B-cell depleting bispecifics, plamotamab and XmAb657, in their respective Phase 1 studies. And we recently started the Phase 1 study of XmAb412, our first XenLock™ bispecific antibody, and plan to have healthy participant data in the first half of 2027. Xencor's focus on clinical execution and data delivery is setting us up for an accelerating tempo of anticipated readouts in 2027 and beyond.”
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$59.1M
EPS estimate-$0.35
Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Xencor report Q2 2026 earnings?
- Xencor (XNCR) reported Q2 2026 earnings on August 5, 2026 after market close.
- What were Xencor's Q2 2026 revenue and EPS?
- Xencor reported revenue of $51.2M and eps of $-0.29 for Q2 2026.
- Did Xencor beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $18.9M by $32.3M. EPS beat the consensus estimate of $-0.80 by $0.51.
- How did Xencor's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 17.5% from $43.6M a year earlier and eps grew 29.3% from $-0.41.
- Where can I find Xencor's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001326732-26-000055) and the 10-Q periodic report (0001326732-26-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.
